Abstract
The incidence of infections due to non-neoformans cryptococcal species is increasing. Risk factors associated with infections due to these organisms include immunosuppression and clinical syndromes are similar to those encountered with Cryptococcus neoformans. Therapy with antifungal agents is often successful.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / therapeutic use
-
Cryptococcosis / drug therapy*
-
Cryptococcosis / epidemiology
-
Cryptococcosis / microbiology
-
Cryptococcus / classification*
-
Cryptococcus / drug effects*
-
Drug Therapy, Combination / therapeutic use
-
Fluconazole / therapeutic use
-
Flucytosine / therapeutic use
-
Humans
Substances
-
Antifungal Agents
-
Amphotericin B
-
Fluconazole
-
Flucytosine